Trial of BMS-986012 in Combination With Platinum and Etoposide

A Phase 1/2 Randomized Trial of BMS-986012 in Combination With Platinum and Etoposide as First-line Therapy in Extensive-Stage Small Cell Lung Cancer

The purpose of this this study is to administer BMS-986012 in Combination with Platinum and Etoposide as First-line Therapy in Extensive Small Cell Lung Cancer.

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

• Male and Females 18 years of age or older
• Pulmonary SCLC documented by histology or cytology
• Extensive disease (Stage IV) SCLC
• Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

Exclusion Criteria:

• Prior systemic therapy for lung cancer
• Symptomatic brain metastases
• Grade 2 peripheral neuropathy
• Active or chronic infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV
• Other active malignancies or prior malignancy within 2 years

Other protocol defined inclusion/exclusion criteria could apply